Diffusion-weighted Imaging in the Follow-up of Treated High-grade Gliomas: Tumor Recurrence Versus Radiation Injury

Overview

Journal AJNR Am J Neuroradiol

Specialty Neurology

Date 2004 Feb 19

PMID 14970018

Citations 153

Authors

Patrick A Hein

Clifford J Eskey

Jeffrey F Dunn

Eugen B Hug

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Diffusion-weighted (DW) MR imaging is a means to characterize and differentiate morphologic features, including edema, necrosis, and tumor tissue, by measuring differences in apparent diffusion coefficient (ADC). We hypothesized that DW imaging has the potential to differentiate recurrent or progressive tumor growth from treatment-induced damage to brain parenchyma in high-grade gliomas after radiation therapy.

Methods: We retrospectively reviewed follow-up conventional and DW MR images obtained starting 1 month after completion of radiation treatment with or without chemotherapy for histologically proved high-grade gliomas. Eighteen patients with areas of abnormal enhancing tissue were identified. ADC maps were calculated from echo-planar DW images, and mean ADC values and ADC ratios (ADC of enhancing lesion to ADC of contralateral white matter) were compared with final diagnosis. Recurrence was established by histologic examination or by clinical course and a combination of imaging studies.

Results: Recurrence and nonrecurrence could be differentiated by using mean ADC values and ADC ratios. ADC ratios in the recurrence group showed significantly lower values (mean +/- SD, 1.43 +/- 0.11) than those of the nonrecurrence group (1.82 +/- 0.07, P <.001). Mean ADCs of the recurrent tumors (mean +/- SD, 1.18 +/- 0.13 x 10(-3) mm/s(2)) were significantly lower than those of the nonrecurrence group (1.40 +/- 0.17 x 10(-3) mm/s(2), P <.006).

Conclusion: Assessment of ADC ratios of enhancing regions in the follow-up of treated high-grade gliomas is useful in differentiating radiation effects from tumor recurrence or progression.

Citing Articles

Novel Fibroblast Growth Factor Receptor 3-Fatty Acid Synthase Gene Fusion in Recurrent Epithelioid Glioblastoma Linked to Aggressive Clinical Progression.

Diaz M, Vazquez-Gomez F, Garrido I, Arias F, Suarez J, Buno I Curr Oncol. 2024; 31(11):7308-7318.

PMID: 39590169 PMC: 11592913. DOI: 10.3390/curroncol31110539.

Is pulsed saturation transfer sufficient for differentiating radiation necrosis from tumor progression in brain metastases?.

Chan R, Lam W, Chen H, Murray L, Zhang B, Theriault A Neurooncol Adv. 2024; 6(1):vdae132.

PMID: 39220250 PMC: 11364936. DOI: 10.1093/noajnl/vdae132.

A bibliometric analysis of radiation-induced brain injury: a research of the literature from 1998 to 2023.

Lan J, Ren Y, Liu Y, Chen L, Liu J Discov Oncol. 2024; 15(1):364.

PMID: 39172266 PMC: 11341524. DOI: 10.1007/s12672-024-01223-6.

Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty.

Salans M, Ni L, Morin O, Ziemer B, Capaldi D, Raleigh D J Neurooncol. 2024; 166(3):535-546.

PMID: 38316705 PMC: 10876820. DOI: 10.1007/s11060-024-04578-6.

Treatment of Central Nervous System Tumors on Combination MR-Linear Accelerators: Review of Current Practice and Future Directions.

Bryant J, Doniparthi A, Weygand J, Cruz-Chamorro R, Oraiqat I, Andreozzi J Cancers (Basel). 2023; 15(21).

PMID: 37958374 PMC: 10649155. DOI: 10.3390/cancers15215200.

References

Schaefer P, Ozsunar Y, He J, Hamberg L, Hunter G, Sorensen A . Assessing tissue viability with MR diffusion and perfusion imaging. AJNR Am J Neuroradiol. 2003; 24(3):436-43. PMC: 7973621. View

Lam W, Poon W, Metreweli C . Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma?. Clin Radiol. 2002; 57(3):219-25. DOI: 10.1053/crad.2001.0741. View

Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K . The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001; 22(6):1081-8. PMC: 7974804. View

Schlemmer H, Bachert P, Henze M, Buslei R, Herfarth K, Debus J . Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology. 2002; 44(3):216-22. DOI: 10.1007/s002340100703. View

Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, Kira T . Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. 2000; 21(5):901-9. PMC: 7976740. View

Stadnik T, Chaskis C, Michotte A, Shabana W, van Rompaey K, Luypaert R . Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol. 2001; 22(5):969-76. PMC: 8174938. View

Graves E, Nelson S, Vigneron D, Verhey L, McDermott M, Larson D . Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol. 2001; 22(4):613-24. PMC: 7976000. View

Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T . Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo). 1998; 38(6):342-7; discussion 347-8. DOI: 10.2176/nmc.38.342. View

Schlemmer H, Bachert P, Herfarth K, Zuna I, Debus J, van Kaick G . Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol. 2001; 22(7):1316-24. PMC: 7975210. View

10.

Tsui E, Chan J, Ramsey R, Leung T, Cheung Y, Luk S . Late temporal lobe necrosis in patients with nasopharyngeal carcinoma: evaluation with combined multi-section diffusion weighted and perfusion weighted MR imaging. Eur J Radiol. 2001; 39(3):133-8. DOI: 10.1016/s0720-048x(01)00328-x. View

11.

Chung J, Kim Y, Kim S, Lee Y, Paek S, Yeo J . Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002; 29(2):176-82. DOI: 10.1007/s00259-001-0690-4. View

12.

Thompson T, Lunsford L, Kondziolka D . Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotact Funct Neurosurg. 2000; 73(1-4):9-14. DOI: 10.1159/000029743. View

13.

Park S, Chang K, Song I, Kim Y, Kim S, Han M . Diffusion-weighted MRI in cystic or necrotic intracranial lesions. Neuroradiology. 2000; 42(10):716-21. DOI: 10.1007/s002340000394. View

14.

Krabbe K, Gideon P, Wagn P, Hansen U, Thomsen C, Madsen F . MR diffusion imaging of human intracranial tumours. Neuroradiology. 1997; 39(7):483-9. DOI: 10.1007/s002340050450. View

15.

Weber W, Bartenstein P, Gross M, Kinzel D, Daschner H, Feldmann H . Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med. 1997; 38(5):802-8. View

16.

Cha S, Knopp E, Johnson G, Litt A, Glass J, Gruber M . Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol. 2000; 21(5):881-90. PMC: 7976741. View

17.

Castillo M, Smith J, Kwock L, Wilber K . Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol. 2001; 22(1):60-4. PMC: 7975568. View

18.

Brunberg J, Chenevert T, McKeever P, Ross D, Junck L, Muraszko K . In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol. 1995; 16(2):361-71. PMC: 8338331. View

19.

Stokkel M, Stevens H, Taphoorn M, van Rijk P . Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study. Nucl Med Commun. 1999; 20(5):411-7. View

20.

Samnick S, Bader J, Hellwig D, Moringlane J, Alexander C, Romeike B . Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol. 2002; 20(2):396-404. DOI: 10.1200/JCO.2002.20.2.396. View